LGL Partners LLC Decreases Stake in SPDR S&P Biotech ETF (NYSEARCA:XBI)

LGL Partners LLC cut its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,349 shares of the exchange traded fund’s stock after selling 1,905 shares during the quarter. LGL Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $1,653,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Addison Advisors LLC lifted its position in SPDR S&P Biotech ETF by 27.4% during the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock worth $48,000 after acquiring an additional 115 shares during the period. Rothschild Investment LLC raised its stake in shares of SPDR S&P Biotech ETF by 3.0% in the fourth quarter. Rothschild Investment LLC now owns 9,655 shares of the exchange traded fund’s stock worth $870,000 after purchasing an additional 282 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of SPDR S&P Biotech ETF by 68.0% during the fourth quarter. IFP Advisors Inc now owns 4,317 shares of the exchange traded fund’s stock worth $389,000 after purchasing an additional 1,747 shares during the period. Wealth Alliance boosted its position in SPDR S&P Biotech ETF by 4.4% in the fourth quarter. Wealth Alliance now owns 4,083 shares of the exchange traded fund’s stock valued at $368,000 after buying an additional 173 shares during the last quarter. Finally, Bank of Jackson Hole Trust purchased a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $43,000.

SPDR S&P Biotech ETF Trading Down 1.6 %

XBI opened at $88.69 on Wednesday. SPDR S&P Biotech ETF has a 12-month low of $81.14 and a 12-month high of $105.47. The firm has a 50 day moving average of $91.14 and a two-hundred day moving average of $95.92. The firm has a market capitalization of $6.76 billion, a PE ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.